QURE uniQure N.V.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1590560 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY28.0%
TTM net income YoY1.0%
TTM EPS YoY20.2%
Revenue 3-yr CAGR-43.5%
Net income 3-yr CAGR—
Margins
Gross margin93.9%
Operating margin-1,001.7%
Net margin-1,154.8%
FCF margin-956.8%
EBITDA margin-921.0%
Returns
ROE-89.0%
ROA-25.5%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets68.7%
Debt / equity0.17x
Current ratio11.52x
Interest coverage-3.51x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $16.10M | $27.12M | $15.84M | $106.48M | $524.00M |
| Cost of revenue | $1.69M | $1.27M | $65,000 | $1.25M | $24.98M |
| Gross profit | $14.41M | $25.85M | $15.78M | $105.23M | $499.03M |
| R&D expense | $140.67M | $143.78M | $214.86M | $197.59M | $143.55M |
| SG&A expense | $65.46M | $52.66M | $74.59M | $55.06M | $56.29M |
| Operating income | -$185.35M | -$184.29M | -$282.87M | -$143.16M | $310.62M |
| Interest expense | $61.99M | $63.74M | $41.56M | $11.70M | $7.47M |
| Pretax income | -$193.34M | -$237.13M | -$306.56M | -$128.26M | $332.81M |
| Income tax | $5.63M | $2.43M | $1.92M | -$1.47M | $3.22M |
| Net income | -$198.97M | -$239.56M | -$308.48M | -$126.79M | $329.59M |
| EBITDA | -$170.59M | -$171.65M | -$270.97M | -$134.96M | $316.72M |
| EPS (basic) | -3.46 | -4.92 | -6.47 | -2.71 | 7.17 |
| EPS (diluted) | -3.46 | -4.92 | -6.47 | -2.71 | 7.04 |
| Weighted avg. shares (diluted) | 57.50M | 48.65M | 47.67M | 46.74M | 46.84M |
| Balance sheet | |||||
| Cash & equivalents | $80.24M | $160.33M | $241.36M | $231.17M | $559.35M |
| Receivables | $5.86M | — | — | — | — |
| Inventory | — | — | $12.02M | $6.92M | — |
| Current assets | $655.99M | $390.29M | $651.85M | $476.77M | $628.24M |
| PP&E, net | $13.80M | $20.42M | $46.55M | $50.53M | $43.51M |
| Goodwill | $25.36M | $22.41M | $26.38M | $25.58M | $27.63M |
| Intangibles | $72.79M | $71.04M | $60.48M | $58.78M | $62.69M |
| Total assets | $824.91M | $556.54M | $831.69M | $704.96M | $809.18M |
| Current liabilities | $62.92M | $40.05M | $73.67M | $75.92M | $36.76M |
| Long-term debt | $49.70M | $51.32M | $101.75M | $102.79M | $100.96M |
| Total debt | $49.70M | $51.32M | $101.75M | $102.79M | $100.96M |
| Total liabilities | $626.01M | $563.29M | $624.02M | $228.96M | $213.40M |
| Shareholders' equity | $198.90M | -$6.75M | $207.67M | $476.01M | $595.78M |
| Net debt | -$30.54M | -$109.00M | -$139.61M | -$128.38M | -$458.39M |
| Shares outstanding | 62.34M | 48.99M | 47.83M | 46.97M | 46.30M |
| Cash flow statement | |||||
| Operating cash flow | -$177.96M | -$182.73M | -$145.93M | -$145.06M | $287.96M |
| Capital expenditure | $439,000 | $3.37M | $7.15M | $17.69M | $17.44M |
| Free cash flow | -$178.40M | -$186.10M | -$153.08M | -$162.75M | $270.52M |
| Investing cash flow | -$321.62M | $162.97M | -$205.69M | -$182.73M | -$67.39M |
| Financing cash flow | $415.40M | -$59.49M | $362.72M | $1.45M | $94.86M |
| Depreciation & amortization | $14.76M | $12.64M | $11.90M | $8.20M | $6.10M |
| Stock-based compensation | $17.68M | $22.26M | $35.09M | $34.20M | $25.64M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.